LABS — Medipharm Labs Cashflow Statement
0.000.00%
Last trade - 00:00- CA$30.30m
- CA$15.49m
- CA$33.06m
- 35
- 67
- 79
- 63
Annual cashflow statement for Medipharm Labs, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 1.13 | -67.1 | -54.8 | -30 | -13.1 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 21.3 | 28.8 | 14.1 | 4.81 | -5.22 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -50.2 | -10.3 | 21.8 | 6.25 | 3.45 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -25.3 | -37.8 | -13.2 | -16.1 | -12.3 |
| Capital Expenditures | -32.4 | -7.5 | -0.783 | -0.863 | -0.471 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.108 | 0.057 | 0.818 | 6.02 | 7.34 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -32.5 | -7.45 | 0.035 | 5.16 | 6.87 |
| Financing Cash Flow Items | -0.311 | -0.965 | -0.151 | 0.403 | 0.576 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 88.5 | 26.4 | 27.8 | 0.796 | -0.368 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 30.8 | -18.7 | 14.2 | -9.96 | -6.16 |